Hosted on MSN
FDA expands Caplyta use, weighs electric shock ban
The FDA has expanded lumateperone (Caplyta) to include relapse prevention in schizophrenia and is considering banning electric shock devices for people with disabilities. These steps come alongside a ...
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...
Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results